From the Research
Gepotidacin is a suitable treatment option for uncomplicated urogenital gonorrhoea, with a microbiological success rate of 92.6% compared to 91.2% for ceftriaxone plus azithromycin, as demonstrated in the EAGLE-1 study 1. The EAGLE-1 study, a phase 3 randomised, open-label, non-inferiority, multicentre study, evaluated the efficacy and safety of gepotidacin for the treatment of uncomplicated urogenital gonorrhoea 1. Key findings from the study include:
- Microbiological success rates of 92.6% in the gepotidacin group and 91.2% in the ceftriaxone plus azithromycin group
- Gepotidacin was non-inferior to ceftriaxone plus azithromycin
- No bacterial persistence of urogenital N gonorrhoeae was observed at test-of-cure for either group
- The gepotidacin group had higher rates of adverse events and drug-related adverse events, mainly due to gastrointestinal adverse events, but most were mild or moderate The study's results suggest that gepotidacin is a viable alternative to traditional treatments for uncomplicated urogenital gonorrhoea, offering a novel oral treatment option with no new safety concerns 1. Some of the other studies provided, such as those on influenza and COVID-19 multicomponent vaccines 2, antihypertensive medication timing 3, and the importance of including unpublished data in systematic reviews 4, are not directly relevant to the question of treating uncomplicated urogenital gonorrhoea. However, the study on the inclusion of effect size measures and clinical relevance in research papers 5 highlights the importance of considering the clinical relevance of study findings, which is relevant to the EAGLE-1 study's findings on the efficacy and safety of gepotidacin. Overall, based on the strongest and most recent evidence, gepotidacin is a recommended treatment option for uncomplicated urogenital gonorrhoea, due to its high microbiological success rate and acceptable safety profile 1.